Cabaletta Bio Investor Relations Material
Latest events
Status Update
Cabaletta Bio
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Cabaletta Bio Inc
Access all reports
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies designed to treat autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania, and its shares are listed on the Nasdaq.
Key slides for Cabaletta Bio Inc
Study Update
Cabaletta Bio Inc
Study Update
Cabaletta Bio Inc
Latest articles
)
The Rise and Fall of Wirecard
A look inside the Wirecard scandal, which took the company from the prestigious DAX 30 to insolvency through the largest accounting fraud in European history.
16 May 2025
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
Ticker symbol
CABA
Country
🇺🇸 United States